Beta Bionics gets FDA clearance for Mint patch pump, cuts 2026 outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm
September 14, 2026 7:30 AM EDTMint features a new and innovative patch pump architecture Full Mint U.S. commercialization expected to begin in Q1 2027 Manufacturing capacity expected to produce at least 1.5 million disposable Mint units during 20273D Intelligence, the Companys next-generation insulin dosing algorithm, has been submitted to the FDA through a 510(k) applicationExpectations to commercialize 3D Intelligence in the U.S. by the end of 2026 as iLet 3D, and at the time of full Mint launch as Mint 3D, subject to regulatory clearance by the FDAUpdated full year... More
